UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy

Frontiers in oncology, 2024-10, Vol.14, p.1473706

2024

Volltextzugriff (PDF)

Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer

Journal of translational medicine, 2024-02, Vol.22 (1), p.141-12, Article 141

2024

Volltextzugriff (PDF)

Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer

Frontiers in immunology, 2024-06, Vol.15, p.1413956

2024

Volltextzugriff (PDF)

4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists

Cancer communications (London, England), 2024-10, Vol.44 (10), p.1168-1172

2024

Volltextzugriff (PDF)

Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?

Oncology and therapy, 2024-03, Vol.12 (1), p.13-17

2024

Volltextzugriff (PDF)

The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer

Oncology and therapy, 2024-06, Vol.12 (2), p.329-343

2024

Volltextzugriff (PDF)

1499 Molecular and immune profiling of lobular-enriched versus non-lobular invasive breast cancers

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1663-A1663

2023

Volltextzugriff (PDF)

183 Comprehensive genomic and immune profiling (CGIP) reveals a distinct genomic and immune gene expression profile for younger patients with non-small cell lung cancer (NSCLC)

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A207-A207

2023

Volltextzugriff (PDF)

176 Immune microenvironment of primary versus metastatic melanoma of the brain

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A200-A200

2023

Volltextzugriff (PDF)

175 Metastatic triple negative breast cancer has distinct tumor immune landscape

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A199-A199

2023

Volltextzugriff (PDF)

513 Comprehensive genomic and immune profiling of ALK fusion-positive and negative lung adenocarcinomas

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A579-A579

2023

Volltextzugriff (PDF)

Abstract PS4-30: Neutrophil-to-lymphocyte ratio or platelet-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic breast cancer treated with CDK4/6 inhibitors

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS4-30-PS4-30

2021

Volltextzugriff (PDF)

Clinical utility of 18F-FDG-PET/CT in staging localized breast cancer prior to initiating preoperative systemic therapy

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.563-563

2020

Volltextzugriff (PDF)

Clinical trial participation in a majority-minority, NCI-designated cancer center

Journal of clinical oncology, 2022-10, Vol.40 (28_suppl), p.86-86

2022

Volltextzugriff (PDF)

Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.3158-3158

2024

Volltextzugriff (PDF)

Testing for FRα in ovarian cancer: Why testing the primary cancer matters more than the metastasis

Gynecologic oncology, 2024-11, Vol.190, p.S192-S192

2024

Volltextzugriff (PDF)

Clinical Outcomes of Acquired Factor VIII Inhibitors in Cancer Population: A Systematic Review

Blood, 2017-12, Vol.130, p.5639-5639

2017

Volltextzugriff (PDF)

87 Distinctions in Tumor Microenvironment Between PD-L1 Positive versus Negative Head and Neck Squamous Cell Carcinoma (HNSCC)

Radiotherapy and oncology, 2024-03, Vol.192, p.S20-S22

2024

Volltextzugriff (PDF)

Real-world clinical and genomic analysis of patients with a personal or family history of cancer undergoing germline testing for BRCA1 and BRCA2

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e22538-e22538

2023

Volltextzugriff (PDF)

Molecular and immune profiling of TP53 -mutated ovarian cancers with non- BRCA1/ 2 homologous recombination gene alterations

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5579-5579

2023

Volltextzugriff (PDF)

Comprehensive genomic and immune profiling of non-V600 BRAF-mutated melanomas: Implications for therapeutic strategies beyond BRAF/MEK inhibitors

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e21544-e21544

2024

Volltextzugriff (PDF)

Predictors of Survival in Patients with Advanced Gastrointestinal Malignancies Admitted to the Intensive Care Unit

The oncologist (Dayton, Ohio), 2019-04, Vol.24 (4), p.483-490

2019

Volltextzugriff (PDF)

Clinical Utility of 18F-FDG PET/CT in Staging Localized Breast Cancer Before Initiating Preoperative Systemic Therapy

Journal of the National Comprehensive Cancer Network, 2020-09, Vol.18 (9), p.1240-1246

2020

Volltextzugriff (PDF)

Hemolytic uremic syndrome associated with Escherichia coli O157:H7 infection in older adults: a case report and review of the literature

Journal of medical case reports, 2016-06, Vol.10 (1), p.175-175, Article 175

2016

Volltextzugriff (PDF)

The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.6506-6506

2023

Volltextzugriff (PDF)

1 – 25 von 132

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(123)
Mit Volltextzugriff
(102)

Publikationsform

Sprache

Englisch
(132)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy

Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer

Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer

4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists

Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?

The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer

1499 Molecular and immune profiling of lobular-enriched versus non-lobular invasive breast cancers

183 Comprehensive genomic and immune profiling (CGIP) reveals a distinct genomic and immune gene expression profile for younger patients with non-small cell lung cancer (NSCLC)

176 Immune microenvironment of primary versus metastatic melanoma of the brain

175 Metastatic triple negative breast cancer has distinct tumor immune landscape

513 Comprehensive genomic and immune profiling of ALK fusion-positive and negative lung adenocarcinomas

Abstract PS4-30: Neutrophil-to-lymphocyte ratio or platelet-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic breast cancer treated with CDK4/6 inhibitors

Clinical utility of 18F-FDG-PET/CT in staging localized breast cancer prior to initiating preoperative systemic therapy

Clinical trial participation in a majority-minority, NCI-designated cancer center

Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors

Testing for FRα in ovarian cancer: Why testing the primary cancer matters more than the metastasis

Clinical Outcomes of Acquired Factor VIII Inhibitors in Cancer Population: A Systematic Review

87 Distinctions in Tumor Microenvironment Between PD-L1 Positive versus Negative Head and Neck Squamous Cell Carcinoma (HNSCC)

Real-world clinical and genomic analysis of patients with a personal or family history of cancer undergoing germline testing for BRCA1 and BRCA2

Molecular and immune profiling of TP53 -mutated ovarian cancers with non- BRCA1/ 2 homologous recombination gene alterations

Comprehensive genomic and immune profiling of non-V600 BRAF-mutated melanomas: Implications for therapeutic strategies beyond BRAF/MEK inhibitors

Predictors of Survival in Patients with Advanced Gastrointestinal Malignancies Admitted to the Intensive Care Unit

Clinical Utility of 18F-FDG PET/CT in Staging Localized Breast Cancer Before Initiating Preoperative Systemic Therapy

Hemolytic uremic syndrome associated with Escherichia coli O157:H7 infection in older adults: a case report and review of the literature

The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program

Suchergebnisse filtern